Corticolimbic Degeneration and Treatment of Dementia

PHASE4CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

November 30, 2004

Primary Completion Date

October 31, 2009

Study Completion Date

October 31, 2009

Conditions
Dementia
Interventions
DRUG

Memantine (Namenda®)

Drug treatment will begin with 5 mg/day of donepezil for six weeks. After six weeks of such treatment, the subjects symptoms will be re-evaluated and any side-effects of treatment assessed and recorded. If no serious side-effects of donepezil are encountered, the dose of donepezil will be increased to 10 mg/day. For subjects prescribed the combination of donepezil and memantine, memantine (20 mg/day) will be added to the drug treatment regimen after the dose of donepezil has been established (i.e., at six weeks). Again, memantine will be initially started at 10 mg/day and increased to its full dose only if no serious side-effects are encountered.

DRUG

Donepezil (Aricept®)

5mg/day for six weeks and if no serious side-effects increased to 10mg/dy.

All Listed Sponsors
collaborator

Northwestern University

OTHER

lead

Washington University School of Medicine

OTHER

NCT00768261 - Corticolimbic Degeneration and Treatment of Dementia | Biotech Hunter | Biotech Hunter